Read the latest positive news, breakthroughs, and inspiring stories about ptsd therapy, curated daily by BrightWire.
The U.S. Department of Veterans Affairs is testing psilocybin therapy for veterans whose depression hasn't responded to traditional treatments. The groundbreaking PIVOT trial will serve veterans at five locations nationwide, offering new hope for those who've exhausted other options.
Over 60% of U.S. voters now strongly support making psychedelics easier to study for medical use, a 14-point jump from 2023. The shift reflects growing public curiosity about therapeutic benefits of substances like psilocybin and MDMA.
The FDA is accelerating reviews of three psychedelic medications for depression and PTSD, moving promising mental health treatments closer to patients who desperately need them. Millions struggling with treatment-resistant conditions could soon have groundbreaking new options.
The FDA is accelerating approval for psilocybin and MDMA-like therapies to treat depression and PTSD, potentially opening new doors for millions struggling with mental health conditions. Three companies are now on an expedited path to bring these promising treatments to patients who haven't found relief from traditional options.